These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27524217)

  • 1. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome.
    Berger BE
    Am J Med Sci; 2016 Aug; 352(2):177-90. PubMed ID: 27524217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical hemolytic uremic syndrome: a syndrome in need of clarity.
    Berger BE
    Clin Kidney J; 2019 Jun; 12(3):338-347. PubMed ID: 31198222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical hemolytic uremic syndrome: Laboratory characteristics, complement-amplifying conditions, renal biopsy, and genetic mutations.
    Hossain MA; Cheema A; Kalathil S; Bajwa R; Costanzo EJ; Cosentino J; Cheng J; Vachharajani T; Asif A
    Saudi J Kidney Dis Transpl; 2018; 29(2):276-283. PubMed ID: 29657193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopathies.
    Cataland SR; Wu HM
    Eur J Intern Med; 2013 Sep; 24(6):486-91. PubMed ID: 23739653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Atypical hemolytic uremic syndrome (aHUS): new insights into pathogenesis leading to novel therapeutic approaches].
    Kistler AD
    Praxis (Bern 1994); 2016 Mar; 105(7):389-96. PubMed ID: 27005733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment.
    Raina R; Krishnappa V; Blaha T; Kann T; Hein W; Burke L; Bagga A
    Ther Apher Dial; 2019 Feb; 23(1):4-21. PubMed ID: 30294946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.
    Laurence J; Haller H; Mannucci PM; Nangaku M; Praga M; Rodriguez de Cordoba S
    Clin Adv Hematol Oncol; 2016 Nov; 14 Suppl 11(11):2-15. PubMed ID: 27930620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management.
    Sridharan M; Go RS; Willrich MAV
    J Immunol Methods; 2018 Oct; 461():15-22. PubMed ID: 30031798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical hemolytic uremic syndrome: from diagnosis to treatment.
    Franchini M
    Clin Chem Lab Med; 2015 Oct; 53(11):1679-88. PubMed ID: 25803082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atypical hemolytic uremic syndrome].
    Blasco Pelicano M; Rodríguez de Córdoba S; Campistol Plana JM
    Med Clin (Barc); 2015 Nov; 145(10):438-45. PubMed ID: 25433773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura.
    Oh J; Oh D; Lee SJ; Kim JO; Kim NK; Chong SY; Huh JY; Baker RI;
    Blood Res; 2019 Sep; 54(3):218-228. PubMed ID: 31730685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG; Kirsztajn GM
    J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.
    Asif A; Nayer A; Haas CS
    J Nephrol; 2017 Jun; 30(3):347-362. PubMed ID: 27848226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis.
    Laurence J
    Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 17):1-12. PubMed ID: 23187605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan.
    Yoshida Y; Miyata T; Matsumoto M; Shirotani-Ikejima H; Uchida Y; Ohyama Y; Kokubo T; Fujimura Y
    PLoS One; 2015; 10(5):e0124655. PubMed ID: 25951460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.
    Cataland SR; Holers VM; Geyer S; Yang S; Wu HM
    Blood; 2014 Jun; 123(24):3733-8. PubMed ID: 24695849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atypical hemolytic uremic syndrome caused by primary complement defects].
    Reusz G
    Orv Hetil; 2018 Jun; 159(23):929-936. PubMed ID: 29860884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome.
    Sperati CJ; Moliterno AR
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):541-59. PubMed ID: 26043391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.